Keryx Biopharmaceuticals Inc.'s iron-based phosphate binder Zerenex (ferric citrate) met the primary and key secondary endpoints in a short-term Phase III trial in hyperphosphatemia in dialysis patients, results that bode well for the ongoing long-term study as well as for the drug's potential in the $1.5 billion phosphate binder market. (BioWorld Today)